BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 15827332)

  • 1. Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells.
    Yip-Schneider MT; Nakshatri H; Sweeney CJ; Marshall MS; Wiebke EA; Schmidt CM
    Mol Cancer Ther; 2005 Apr; 4(4):587-94. PubMed ID: 15827332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac.
    Yip-Schneider MT; Schmidt CM
    Pancreas; 2003 Nov; 27(4):337-44. PubMed ID: 14576498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dimethylamino parthenolide enhances the inhibitory effects of gemcitabine in human pancreatic cancer cells.
    Holcomb BK; Yip-Schneider MT; Waters JA; Beane JD; Crooks PA; Schmidt CM
    J Gastrointest Surg; 2012 Jul; 16(7):1333-40. PubMed ID: 22618517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo.
    Yip-Schneider MT; Wu H; Ralstin M; Yiannoutsos C; Crooks PA; Neelakantan S; Noble S; Nakshatri H; Sweeney CJ; Schmidt CM
    Mol Cancer Ther; 2007 Jun; 6(6):1736-44. PubMed ID: 17541034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parthenolide cooperates with NS398 to inhibit growth of human hepatocellular carcinoma cells through effects on apoptosis and G0-G1 cell cycle arrest.
    Ralstin MC; Gage EA; Yip-Schneider MT; Klein PJ; Wiebke EA; Schmidt CM
    Mol Cancer Res; 2006 Jun; 4(6):387-99. PubMed ID: 16778086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the phosphatidylinositol 3'-kinase signaling pathway increases the responsiveness of pancreatic carcinoma cells to sulindac.
    Yip-Schneider MT; Wiesenauer CA; Schmidt CM
    J Gastrointest Surg; 2003; 7(3):354-63. PubMed ID: 12654560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells.
    Wang W; Adachi M; Zhang R; Zhou J; Zhu D
    Pancreas; 2009 May; 38(4):e114-23. PubMed ID: 19342982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Natural Product Parthenolide Inhibits Both Angiogenesis and Invasiveness and Improves Gemcitabine Resistance by Suppressing Nuclear Factor κB Activation in Pancreatic Cancer Cell Lines.
    Denda Y; Matsuo Y; Sugita S; Eguchi Y; Nonoyama K; Murase H; Kato T; Imafuji H; Saito K; Morimoto M; Ogawa R; Takahashi H; Mitsui A; Kimura M; Takiguchi S
    Nutrients; 2024 Feb; 16(5):. PubMed ID: 38474833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sesquiterpene lactone parthenolide suppresses tumor growth in a xenograft model of renal cell carcinoma by inhibiting the activation of NF-kappaB.
    Oka D; Nishimura K; Shiba M; Nakai Y; Arai Y; Nakayama M; Takayama H; Inoue H; Okuyama A; Nonomura N
    Int J Cancer; 2007 Jun; 120(12):2576-81. PubMed ID: 17290398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combinatorial effect of non-steroidal anti-inflammatory drugs and NF-κB inhibitors in ovarian cancer therapy.
    Zerbini LF; Tamura RE; Correa RG; Czibere A; Cordeiro J; Bhasin M; Simabuco FM; Wang Y; Gu X; Li L; Sarkar D; Zhou JR; Fisher PB; Libermann TA
    PLoS One; 2011; 6(9):e24285. PubMed ID: 21931671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parthenolide induces proliferation inhibition and apoptosis of pancreatic cancer cells in vitro.
    Liu JW; Cai MX; Xin Y; Wu QS; Ma J; Yang P; Xie HY; Huang DS
    J Exp Clin Cancer Res; 2010 Aug; 29(1):108. PubMed ID: 20698986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Parthenolide and Balsalazide Have Enhanced Antitumor Efficacy Through Blockade of NF-κB Activation.
    Kim SL; Kim SH; Park YR; Liu YC; Kim EM; Jeong HJ; Kim YN; Seo SY; Kim IH; Lee SO; Lee ST; Kim SW
    Mol Cancer Res; 2017 Feb; 15(2):141-151. PubMed ID: 28108625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel efficacy is increased by parthenolide via nuclear factor-kappaB pathways in in vitro and in vivo human non-small cell lung cancer models.
    Gao ZW; Zhang DL; Guo CB
    Curr Cancer Drug Targets; 2010 Nov; 10(7):705-15. PubMed ID: 20578985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parthenolide, a natural inhibitor of Nuclear Factor-kappaB, inhibits lung colonization of murine osteosarcoma cells.
    Kishida Y; Yoshikawa H; Myoui A
    Clin Cancer Res; 2007 Jan; 13(1):59-67. PubMed ID: 17200339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of NF-kappaB activity by parthenolide induces X-ray sensitivity through inhibition of split-dose repair in TP53 null prostate cancer cells.
    Watson C; Miller DA; Chin-Sinex H; Losch A; Hughes W; Sweeney C; Mendonca MS
    Radiat Res; 2009 Apr; 171(4):389-96. PubMed ID: 19397439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sesquiterpene lactone parthenolide markedly enhances sensitivity of human A549 cells to low-dose oxaliplatin via inhibition of NF-kappaB activation and induction of apoptosis.
    Fang LJ; Shao XT; Wang S; Lu GH; Xu T; Zhou JY
    Planta Med; 2010 Feb; 76(3):258-64. PubMed ID: 19774508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of dimethylaminoparthenolide and sulindac in combination with gemcitabine in a genetically engineered mouse model of pancreatic cancer.
    Yip-Schneider MT; Wu H; Hruban RH; Lowy AM; Crooks PA; Schmidt CM
    Pancreas; 2013 Jan; 42(1):160-7. PubMed ID: 22699205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimyeloma effects of a sesquiterpene lactone parthenolide.
    Suvannasankha A; Crean CD; Shanmugam R; Farag SS; Abonour R; Boswell HS; Nakshatri H
    Clin Cancer Res; 2008 Mar; 14(6):1814-22. PubMed ID: 18347184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic cytotoxic effect of sulindac and pyrrolidine dithiocarbamate against ovarian cancer cells.
    Jakubowska-Mućka A; Sieńko J; Zapała Ł; Wolny R; Lasek W
    Oncol Rep; 2012 Apr; 27(4):1245-50. PubMed ID: 22266802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic cancer cell genetics and signaling response to treatment correlate with efficacy of gemcitabine-based molecular targeting strategies.
    Holcomb B; Yip-Schneider MT; Matos JM; Dixon J; Kennard J; Mahomed J; Shanmugam R; Sebolt-Leopold J; Schmidt CM
    J Gastrointest Surg; 2008 Feb; 12(2):288-96. PubMed ID: 18049840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.